This site displays a prototype of a “Web 2.0” version of the daily
Federal Register. It is not an official legal edition of the Federal
Register, and does not replace the official print version or the official
electronic version on GPO’s govinfo.gov.
The documents posted on this site are XML renditions of published Federal
Register documents. Each document posted on the site includes a link to the
corresponding official PDF file on govinfo.gov. This prototype edition of the
daily Federal Register on FederalRegister.gov will remain an unofficial
informational resource until the Administrative Committee of the Federal
Register (ACFR) issues a regulation granting it official legal status.
For complete information about, and access to, our official publications
and services, go to
About the Federal Register
on NARA's archives.gov.
The OFR/GPO partnership is committed to presenting accurate and reliable
regulatory information on FederalRegister.gov with the objective of
establishing the XML-based Federal Register as an ACFR-sanctioned
publication in the future. While every effort has been made to ensure that
the material on FederalRegister.gov is accurately displayed, consistent with
the official SGML-based PDF version on govinfo.gov, those relying on it for
legal research should verify their results against an official edition of
the Federal Register. Until the ACFR grants it official status, the XML
rendition of the daily Federal Register on FederalRegister.gov does not
provide legal notice to the public or judicial notice to the courts.
Notice
Enter a search term or FR citation e.g.
88 FR 38230 FR 78782024-13208USDA09/05/24RULE0503-AA39SORN
Choosing an item from
full text search results
will bring you to those results. Pressing enter in the search box
will also bring you to search results.
Choosing an item from
suggestions
will bring you directly to the content.
Authority for these committees will expire on the dates indicated in the following table unless the Commissioner formally determines that renewal is in the public interest.
Table of Contents
Enhanced Content - Table of Contents
This table of contents is a navigational tool, processed from the
headings within the legal text of Federal Register documents.
This repetition of headings to form internal navigation links
has no substantive legal effect.
Document page views are updated periodically throughout the day and are
cumulative counts for this document. Counts are subject to sampling,
reprocessing and revision (up or down) throughout the day.
Page views
139
as of
11/09/2026 at 8:15 am EST
Other Formats
Enhanced Content - Other Formats
This document is also available in the following formats:
This PDF is FR Doc. 2014-20017 as it appeared on Public Inspection on
08/22/2014 at 8:45 am.
If you are using public inspection listings for legal research, you
should verify the contents of the documents against a final, official
edition of the Federal Register. Only official editions of the
Federal Register provide legal notice of publication to the public and judicial notice
to the courts under 44 U.S.C. 1503 & 1507.
Learn more here.
Published Document: 2014-20017 (79 FR 50658)
This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Notice.
SUMMARY:
The Food and Drug Administration (FDA) is announcing the renewal of certain FDA advisory committees by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the
( printed page 50659)
charters of the committees listed in the following table for an additional 2 years beyond charter expiration date. The new charters will be in effect until the dates of expiration listed in the following table.
DATES:
Authority for these committees will expire on the dates indicated in the following table unless the Commissioner formally determines that renewal is in the public interest.
—
Name of committee
Date of expiration
Advisory Committee for Pharmaceutical Science and Clinical Pharmacology
January 22, 2016.
Gastrointestinal Drugs Advisory Committee
March 3, 2016.
Bone, Reproductive and Urologic Drugs Advisory Committee (formerly Reproductive Health Drugs Advisory Committee)
March 23, 2016.
April 5, 2016.
Arthritis Advisory Committee
April 25, 2016.
Pharmacy Compounding Advisory Committee
May 1, 2016.
Anesthetic and Analgesic Drugs Advisory Committee
May 13, 2016.
Blood Products Advisory Committee
May 30, 2016.
Pulmonary-Allergy Drugs Advisory Committee
May 31, 2016.
Drug Safety and Risk Management Advisory Committee
June 2, 2016.
Science Advisory Board to the National Center for Toxicological Research
June 4, 2016.
Peripheral and Central Nervous System Drugs Advisory Committee
June 4, 2016.
Psychopharmacologic Drugs Advisory Committee
June 9, 2016.
Transmissible and Spongiform Encephalopathies Advisory Committee
June 26, 2016.
Science Board to the Food and Drug Administration
July 9, 2016.
Allergenic Products Advisory Committee
FOR FURTHER INFORMATION CONTACT:
Michael Ortwerth, Director, Advisory Committee Oversight and Management Staff, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993-0002, 301-443-0572 or 1-800-741-8138. For further information related to FDA advisory committees please visit us at:
http://www.fda.gov/AdvisoryCommittees/default.htm.
This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2).